Therapy response and outcome of overlap syndromes: Autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis

Hepato-Gastroenterology

Volumn 57, Issue 99-100, 2010, Pages 441-446

  Ozaslan, Ersan ^a   Efe, Cumali ^a   Akbulut, Sabiye ^a   Purnak, Tugrul ^a   Savas, Berna ^b   Erden, Esra ^b   Altiparmak, Emin ^a  

^a Numune Education and Research Hospital   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

AMA negative primary biliary cirrhosis; Autoimmune cholangitis; Autoimmune hepatitis; Primary biliary cirrhosis; Therapy

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOGLOBULIN M; PREDNISOLONE; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER FAILURE; MALE; MONOTHERAPY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AUTOIMMUNE DISEASES; CHOLANGITIS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; PREDNISOLONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 77955507384     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Czaja AJ: The variant forms of autoimmune hepatitis. Ann Intern Med 1996;125:588-98.
2. Czaja AJ: Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360-5.
3. Beuers U: Hepatic overlap syndromes. J Hepatol 2005; 42:93-99.
4. Poupon RE, Poupon R, Balkàu B, UCDA-PBC study group: Ursodiol for the long term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1386-7.
5. Alvarez A, Berg PA, Bianchi FB, et al: International Autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
6. Lohse AW, zum Buschenfelde KH, Franz B, et al: Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: Evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29:1078-84.
7. Chazouillères O, Wendum D, Serfaty L, et al: Long term outcome and response to therapy of primary biliary cirrhosis - autoimmune hepatitis overlap syndrome, J Hepatol 2006;44: 400-406.
8. Joshi S, Cauch-Dudek K, Wanless IR, et al: Primary biliary cirrhosis with additional features of autoimmune hepatitis: Response to therapy with ursodeoxycholic acid. Hepatology 2002;35:409-13.
9. Brunner G, Klinge O: A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis). Dtsch Med Wochenschr 1987;112:1454-1458.
10. Czaja AJ, Carpenter HA, Santrach PJ, et al: Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31:1231-1238.
11. Invernizzi P, Crosignani A, Battezzati PM, et al: Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997;25: 1090-1095.
12. Heathcote EJ: Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000; 31:1005-1013.
13. Miyakawa H, Tanaka A, Kikuchi K, et al: Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens, Hepatology 2001;34:243-248.
14. Li CP, Tong MJ, Hwang SJ, et al: Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursode-oxycholic acid, J Gastroenterol Hepatol 2000;15:95-98.
15. Alric L, Thebault S, Selves J, et al: Characterization of overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis according to antimitochondrial antibodies status. Gastroenterol Clin Biol. 2007;31:11-6.
16. Chazouillères O, D. Wendum D, L. Serfaty L, et al: Primary biliary cirrhosis - autoimmune hepatitis overlap syndrome: clinical features and response to therapy, Hepatology 1998;28:296-301.
17. The METAVIR Cooperative Group: Inter- and intraobserver variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994;20:15-20.
18. Ludwig J, Dickson ER, McDonald GSA: Staging of chronic non-suppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histopathol 1978;379:103-12.
19. Czaja AJ, Freese DK; American Association for the Study of Liver Disease: Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479-97.
20. Silveira MG, Talwalkar JA, Angulo P, et al: Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007;102:1244-50.
21. Gisbert JP, Jones EA, Pajares JM, et al: Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? Aliment Pharmacol Ther 2003;17:17-27.
22. Ben-Ari Z, Dhillon AP, Sherlock S: Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993;18:10-5.
23. Sánchez-Pobre P, Castellano G, Colina F, et al: Antimitochondrial antibody-negative chronic nonsuppurative destructive cholangitis. Atypical primary biliary cirrhosis or autoimmune cholangitis? J Clin Gastroenterol 1996;23:191-8.
24. Sherlock S: Ludwig Symposium on biliary disorders. Autoimmune cholangitis: a unique entity? Mayo Clin Proc 1998;73:184-90.
25. Masumoto T, Ninomiya T, Michitaka K, et al: Three patients with autoimmune cholangiopathy treated with prednisolone. J Gastroenterol 1998;33:909-13.